Subject:
- Active Substance: Alecitinib
- Name: Alecensa©
- Therapeutic area: Non-small cell lung cancer (NSCLC)
- Pharmaceutical company: Roche Pharma AG
Time table:
- Publication of project plan: 20.10.2018
- Publication of final assessment: 23.01.2018
Assessment information:
- Title: Alecitinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer
- Author/Co-Author: TLV (Sweden), HVB (Austria), AAZ (Croatia)
- Dedicated Reviewers: NICE (UK), Regione Veneto (Italy), AETSA (Spain), NIPN (Hungary)
- Information retrieval: IQWiG (Germany)
- Observer: MoH (Malta)
› G-BA assessment available (D-326)